IRCT20230910059395N1 IRCT 2023-11-18 Oroumia University of Medical Sciences Investigating the effect of Gliclazide-MR on glycaemic control in type 2 diabetic patients Comparing the effect of basal insulin with modified-release gliclazide on glycemic control in type 2 diabetic patients with HbA1C above 10% 2023-12-22 anticipated 90 Complete https://irct.ir/trial/73598 interventional Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: Patients will be divided into two groups using the block randomization method based on generated numbers by Random allocation software. Thus, in this software, first, the number of groups and the total determined sample size will be entered, and then in the block section, the Block randomization method will be implemented. According to the total sample size (90 patients), 23 blocks of 4 will be used. Then, the computer-generated numbers list will be given to the physician, and the physician will assign patients to groups according to the determined order by the software for entry into one of the groups. 3 Type 2 diabetes. Intervention 1: Intervention group: For patients, in addition to the drugs they receive for glycemic control, gliclazide-MR 30 mg (produced by Actoverco pharmaceutical company) twice a day will be prescribed for three months. Intervention 2: Control group: For patients, in addition to the drugs they receive for glycemic control, basal insulin 0.1-0.3 u/kg (produced by Pouyesh Daru Company) will be prescribed for three months. No - There is not a plan to make this available Justification or reason for not sharing IPD is There is no more information